Home › New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions
 

Keywords :   


New Data from IMPROVE-IT Study of VYTORIN (ezetimibe/simvastatin) and TRA 2P TIMI 50 Study of ZONTIVITY (vorapaxar) to be Presented at American College of Cardiology Scientific Sessions

2015-02-25 14:00:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Investigational data from IMPROVE-IT to be announced in Featured Clinical Research Session II KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that new data from two trials of the companys cardiovascular medicines will be presented at the 2015 American College of Cardiology Annual Scientific Sessions (ACC.15), March 14-16 in San Diego. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orMichael Close, 267-305-1211orInvestor:Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: of data american study

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.11Boeing strike ends as workers back 38% pay rise deal
05.11Tropical Storm Rafael Public Advisory Number 6A
05.11Summary for Tropical Storm Rafael (AT3/AL182024)
05.11Tropical Storm Rafael Graphics
05.11Atlantic Tropical Weather Outlook
05.11Eastern North Pacific Tropical Weather Outlook
05.11Tropical Storm Rafael Graphics
05.11Tropical Storm Rafael Forecast Discussion Number 6
More »